APO Research
Talk to an analyst

APO RESEARCH · REPORT

Bi-Specific Antibodies Therapy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Bi-Specific Antibodies Therapy Market Outlook and Growth Opportunities 2026

29 December 2025194 pages

Choose your research edition.

Industry ResearchBi-Specific Antibodies Therapy Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Bi-Specific Antibodies Therapy Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Bi-Specific Antibodies Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Bi-Specific Antibodies Therapy Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Bi-Specific Antibodies Therapy Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Bi-Specific Antibodies Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Bi-Specific Antibodies Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Bi-Specific Antibodies Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Bi-Specific Antibodies Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Bi-Specific Antibodies Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Bi-Specific Antibodies Therapy market include Alphamab Co. Ltd, Genmab, Lindis Biotech, MacroGenics, Inc, AstraZeneca, AbbVie, Amgen, Pfizer and Akeso, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Bi-Specific Antibodies Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Bi-Specific Antibodies Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Bi-Specific Antibodies Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Bi-Specific Antibodies Therapy market.

Bi-Specific Antibodies Therapy Segment by Company

Alphamab Co. Ltd

Genmab

Lindis Biotech

MacroGenics, Inc

AstraZeneca

AbbVie

Amgen

Pfizer

Akeso, Inc.

Roche

Johnson & Johnson

Sanofi

Bi-Specific Antibodies Therapy Segment by Type

Fragment-Based Antibodies

IgG-Based Antibodies

Bi-Specific Antibodies Therapy Segment by Application

Cancer

Haemophilia

Other Non-Cancer Diseases

Bi-Specific Antibodies Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Bi-Specific Antibodies Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Bi-Specific Antibodies Therapy key companies, revenue, market share, and recent developments.

3. To split the Bi-Specific Antibodies Therapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Bi-Specific Antibodies Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Bi-Specific Antibodies Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze Bi-Specific Antibodies Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bi-Specific Antibodies Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Bi-Specific Antibodies Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bi-Specific Antibodies Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Bi-Specific Antibodies Therapy industry.

Chapter 3: Detailed analysis of Bi-Specific Antibodies Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Bi-Specific Antibodies Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Bi-Specific Antibodies Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Bi-Specific Antibodies Therapy Industry Trends Table 2. Bi-Specific Antibodies Therapy Industry Drivers Table 3. Bi-Specific Antibodies Therapy Industry Opportunities and Challenges Table 4. Bi-Specific Antibodies Therapy Industry Restraints Table 5. Global Bi-Specific Antibodies Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Bi-Specific Antibodies Therapy Revenue Share by Company (2021-2026) Table 7. Global Bi-Specific Antibodies Therapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Bi-Specific Antibodies Therapy Key Company Manufacturing Base & Headquarters Table 9. Global Bi-Specific Antibodies Therapy Company, Product Type & Application Table 10. Global Bi-Specific Antibodies Therapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Bi-Specific Antibodies Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Fragment-Based Antibodies Table 15. Significant Companies of IgG-Based Antibodies Table 16. Global Bi-Specific Antibodies Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Bi-Specific Antibodies Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Bi-Specific Antibodies Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Bi-Specific Antibodies Therapy Sales Value Share by Type (2021-2026) Table 20. Global Bi-Specific Antibodies Therapy Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Cancer Table 22. Significant Companies of Haemophilia Table 23. Significant Companies of Other Non-Cancer Diseases Table 24. Global Bi-Specific Antibodies Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Bi-Specific Antibodies Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Bi-Specific Antibodies Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Bi-Specific Antibodies Therapy Sales Value Share by Application (2021-2026) Table 28. Global Bi-Specific Antibodies Therapy Sales Value Share by Application (2027-2032) Table 29. Global Bi-Specific Antibodies Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Bi-Specific Antibodies Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Bi-Specific Antibodies Therapy Sales Value Share by Region (2021-2026) Table 32. Global Bi-Specific Antibodies Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Bi-Specific Antibodies Therapy Sales Value Share by Region (2027-2032) Table 34. Global Bi-Specific Antibodies Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Bi-Specific Antibodies Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Bi-Specific Antibodies Therapy Sales Value Market Share by Country (2021-2026) Table 37. Global Bi-Specific Antibodies Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Bi-Specific Antibodies Therapy Sales Value Market Share by Country (2027-2032) Table 39. Alphamab Co. Ltd Company Information Table 40. Alphamab Co. Ltd Business Overview Table 41. Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Alphamab Co. Ltd Bi-Specific Antibodies Therapy Product Portfolio Table 43. Alphamab Co. Ltd Recent Development Table 44. Genmab Company Information Table 45. Genmab Business Overview Table 46. Genmab Bi-Specific Antibodies Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Genmab Bi-Specific Antibodies Therapy Product Portfolio Table 48. Genmab Recent Development Table 49. Lindis Biotech Company Information Table 50. Lindis Biotech Business Overview Table 51. Lindis Biotech Bi-Specific Antibodies Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Lindis Biotech Bi-Specific Antibodies Therapy Product Portfolio Table 53. Lindis Biotech Recent Development Table 54. MacroGenics, Inc Company Information Table 55. MacroGenics, Inc Business Overview Table 56. MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. MacroGenics, Inc Bi-Specific Antibodies Therapy Product Portfolio Table 58. MacroGenics, Inc Recent Development Table 59. AstraZeneca Company Information Table 60. AstraZeneca Business Overview Table 61. AstraZeneca Bi-Specific Antibodies Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. AstraZeneca Bi-Specific Antibodies Therapy Product Portfolio Table 63. AstraZeneca Recent Development Table 64. AbbVie Company Information Table 65. AbbVie Business Overview Table 66. AbbVie Bi-Specific Antibodies Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. AbbVie Bi-Specific Antibodies Therapy Product Portfolio Table 68. AbbVie Recent Development Table 69. Amgen Company Information Table 70. Amgen Business Overview Table 71. Amgen Bi-Specific Antibodies Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Amgen Bi-Specific Antibodies Therapy Product Portfolio Table 73. Amgen Recent Development Table 74. Pfizer Company Information Table 75. Pfizer Business Overview Table 76. Pfizer Bi-Specific Antibodies Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Pfizer Bi-Specific Antibodies Therapy Product Portfolio Table 78. Pfizer Recent Development Table 79. Akeso, Inc. Company Information Table 80. Akeso, Inc. Business Overview Table 81. Akeso, Inc. Bi-Specific Antibodies Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Akeso, Inc. Bi-Specific Antibodies Therapy Product Portfolio Table 83. Akeso, Inc. Recent Development Table 84. Roche Company Information Table 85. Roche Business Overview Table 86. Roche Bi-Specific Antibodies Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Roche Bi-Specific Antibodies Therapy Product Portfolio Table 88. Roche Recent Development Table 89. Johnson & Johnson Company Information Table 90. Johnson & Johnson Business Overview Table 91. Johnson & Johnson Bi-Specific Antibodies Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Johnson & Johnson Bi-Specific Antibodies Therapy Product Portfolio Table 93. Johnson & Johnson Recent Development Table 94. Sanofi Company Information Table 95. Sanofi Business Overview Table 96. Sanofi Bi-Specific Antibodies Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Sanofi Bi-Specific Antibodies Therapy Product Portfolio Table 98. Sanofi Recent Development Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Bi-Specific Antibodies Therapy Product Image Figure 2. Global Bi-Specific Antibodies Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Bi-Specific Antibodies Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Bi-Specific Antibodies Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Fragment-Based Antibodies Image Figure 8. IgG-Based Antibodies Image Figure 9. Global Bi-Specific Antibodies Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Bi-Specific Antibodies Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Bi-Specific Antibodies Therapy Sales Value Share by Type (2021-2032) Figure 12. Cancer Image Figure 13. Haemophilia Image Figure 14. Other Non-Cancer Diseases Image Figure 15. Global Bi-Specific Antibodies Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Bi-Specific Antibodies Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Bi-Specific Antibodies Therapy Sales Value Share by Application (2021-2032) Figure 18. Global Bi-Specific Antibodies Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Bi-Specific Antibodies Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Bi-Specific Antibodies Therapy Sales Value (2021-2032) & (US$ Million) Figure 21. North America Bi-Specific Antibodies Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Bi-Specific Antibodies Therapy Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Bi-Specific Antibodies Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Bi-Specific Antibodies Therapy Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Bi-Specific Antibodies Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Bi-Specific Antibodies Therapy Sales Value (2021-2032) & (US$ Million) Figure 27. South America Bi-Specific Antibodies Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Bi-Specific Antibodies Therapy Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Bi-Specific Antibodies Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Fragment-Based Antibodies
  • IgG-Based Antibodies
Applications
  • Cancer
  • Haemophilia
  • Other Non-Cancer Diseases
Companies covered
  • Alphamab Co. Ltd
  • Genmab
  • Lindis Biotech
  • MacroGenics, Inc
  • AstraZeneca
  • AbbVie
  • Amgen
  • Pfizer
  • Akeso, Inc.
  • Roche
  • Johnson & Johnson
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Bi-Specific Antibodies Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Bi-Specific Antibodies Therapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Bi-Specific Antibodies Therapy Market Dynamics
  1. 2.1 Bi-Specific Antibodies Therapy Industry Trends
  2. 2.2 Bi-Specific Antibodies Therapy Industry Drivers
  3. 2.3 Bi-Specific Antibodies Therapy Industry Opportunities and Challenges
  4. 2.4 Bi-Specific Antibodies Therapy Industry Restraints
3 Bi-Specific Antibodies Therapy Market by Company
  1. 3.1 Global Bi-Specific Antibodies Therapy Company Revenue Ranking in 2025
  2. 3.2 Global Bi-Specific Antibodies Therapy Revenue by Company (2021-2026)
  3. 3.3 Global Bi-Specific Antibodies Therapy Company Ranking (2024-2026)
  4. 3.4 Global Bi-Specific Antibodies Therapy Company Manufacturing Base and Headquarters
  5. 3.5 Global Bi-Specific Antibodies Therapy Company Product Type and Application
  6. 3.6 Global Bi-Specific Antibodies Therapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Bi-Specific Antibodies Therapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Bi-Specific Antibodies Therapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Bi-Specific Antibodies Therapy Market by Type
  1. 4.1 Bi-Specific Antibodies Therapy Type Introduction
  2. 4.1.1 Fragment-Based Antibodies
  3. 4.1.2 IgG-Based Antibodies
  4. 4.2 Global Bi-Specific Antibodies Therapy Sales Value by Type
  5. 4.2.1 Global Bi-Specific Antibodies Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Bi-Specific Antibodies Therapy Sales Value by Type (2021-2032)
  7. 4.2.3 Global Bi-Specific Antibodies Therapy Sales Value Share by Type (2021-2032)
5 Bi-Specific Antibodies Therapy Market by Application
  1. 5.1 Bi-Specific Antibodies Therapy Application Introduction
  2. 5.1.1 Cancer
  3. 5.1.2 Haemophilia
  4. 5.1.3 Other Non-Cancer Diseases
  5. 5.2 Global Bi-Specific Antibodies Therapy Sales Value by Application
  6. 5.2.1 Global Bi-Specific Antibodies Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Bi-Specific Antibodies Therapy Sales Value by Application (2021-2032)
  8. 5.2.3 Global Bi-Specific Antibodies Therapy Sales Value Share by Application (2021-2032)
6 Bi-Specific Antibodies Therapy Regional Value Analysis
  1. 6.1 Global Bi-Specific Antibodies Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Bi-Specific Antibodies Therapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Bi-Specific Antibodies Therapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Bi-Specific Antibodies Therapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Bi-Specific Antibodies Therapy Sales Value (2021-2032)
  7. 6.3.2 North America Bi-Specific Antibodies Therapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Bi-Specific Antibodies Therapy Sales Value (2021-2032)
  10. 6.4.2 Europe Bi-Specific Antibodies Therapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Bi-Specific Antibodies Therapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Bi-Specific Antibodies Therapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Bi-Specific Antibodies Therapy Sales Value (2021-2032)
  16. 6.6.2 South America Bi-Specific Antibodies Therapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Bi-Specific Antibodies Therapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Bi-Specific Antibodies Therapy Sales Value Share by Country, 2025 VS 2032
7 Bi-Specific Antibodies Therapy Country-level Value Analysis
  1. 7.1 Global Bi-Specific Antibodies Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Bi-Specific Antibodies Therapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Bi-Specific Antibodies Therapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Bi-Specific Antibodies Therapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Bi-Specific Antibodies Therapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Bi-Specific Antibodies Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Bi-Specific Antibodies Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Alphamab Co. Ltd
  2. 8.1.1 Alphamab Co. Ltd Company Information
  3. 8.1.2 Alphamab Co. Ltd Business Overview
  4. 8.1.3 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Product Portfolio
  6. 8.1.5 Alphamab Co. Ltd Recent Developments
  7. 8.2 Genmab
  8. 8.2.1 Genmab Company Information
  9. 8.2.2 Genmab Business Overview
  10. 8.2.3 Genmab Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Genmab Bi-Specific Antibodies Therapy Product Portfolio
  12. 8.2.5 Genmab Recent Developments
  13. 8.3 Lindis Biotech
  14. 8.3.1 Lindis Biotech Company Information
  15. 8.3.2 Lindis Biotech Business Overview
  16. 8.3.3 Lindis Biotech Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Lindis Biotech Bi-Specific Antibodies Therapy Product Portfolio
  18. 8.3.5 Lindis Biotech Recent Developments
  19. 8.4 MacroGenics, Inc
  20. 8.4.1 MacroGenics, Inc Company Information
  21. 8.4.2 MacroGenics, Inc Business Overview
  22. 8.4.3 MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 MacroGenics, Inc Bi-Specific Antibodies Therapy Product Portfolio
  24. 8.4.5 MacroGenics, Inc Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Bi-Specific Antibodies Therapy Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 AbbVie
  32. 8.6.1 AbbVie Company Information
  33. 8.6.2 AbbVie Business Overview
  34. 8.6.3 AbbVie Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AbbVie Bi-Specific Antibodies Therapy Product Portfolio
  36. 8.6.5 AbbVie Recent Developments
  37. 8.7 Amgen
  38. 8.7.1 Amgen Company Information
  39. 8.7.2 Amgen Business Overview
  40. 8.7.3 Amgen Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Amgen Bi-Specific Antibodies Therapy Product Portfolio
  42. 8.7.5 Amgen Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Bi-Specific Antibodies Therapy Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Akeso, Inc.
  50. 8.9.1 Akeso, Inc. Company Information
  51. 8.9.2 Akeso, Inc. Business Overview
  52. 8.9.3 Akeso, Inc. Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Akeso, Inc. Bi-Specific Antibodies Therapy Product Portfolio
  54. 8.9.5 Akeso, Inc. Recent Developments
  55. 8.10 Roche
  56. 8.10.1 Roche Company Information
  57. 8.10.2 Roche Business Overview
  58. 8.10.3 Roche Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Roche Bi-Specific Antibodies Therapy Product Portfolio
  60. 8.10.5 Roche Recent Developments
  61. 8.11 Johnson & Johnson
  62. 8.11.1 Johnson & Johnson Company Information
  63. 8.11.2 Johnson & Johnson Business Overview
  64. 8.11.3 Johnson & Johnson Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Johnson & Johnson Bi-Specific Antibodies Therapy Product Portfolio
  66. 8.11.5 Johnson & Johnson Recent Developments
  67. 8.12 Sanofi
  68. 8.12.1 Sanofi Company Information
  69. 8.12.2 Sanofi Business Overview
  70. 8.12.3 Sanofi Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sanofi Bi-Specific Antibodies Therapy Product Portfolio
  72. 8.12.5 Sanofi Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst